Loading stock data…
Incyte Corporation (INCY)
$114.66+0.91 (+0.80%)
Market ClosedLast close Jun 29
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Incyte Corporation in the Healthcare sector is trading at $114.66 with a market capitalization of $22.9B. Wall Street consensus targets $110.70 (23 analysts), implying a -3.5% move over the next 12 months. The stock is currently near its 52-week high of $115.56, remaining 17.6% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.27B↓ | $1.51B↑ | $1.37B↑ | $1.22B↑ | $1.05B |
| Gross Profit | $1.17B↓ | $1.39B↑ | $1.27B↑ | $1.14B↑ | $979.70M |
| Operating Income | $324.17M↓ | $383.96M↓ | $431.30M↑ | $310.81M↑ | $216.72M |
| Net Income | $303.33M↑ | $299.28M↓ | $424.17M↑ | $405.00M↑ | $158.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycyth...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.91B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.22
Beta
Defensive asset. Lower volatility than the S&P 500.
0.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
25.46%
Volume
Today's trading volume
1.40M
Recent News
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Incyte (INCY) Stock After 66% One-Year Rally Is The Market Too Optimistic Now
If you are wondering whether Incyte stock still offers value after a strong run, this article breaks down what the current price might be implying about the company. Incyte closed at US$113.75, with returns of 15.8% over 7 days, 16.9% over 30 days, 12.2% year to date, 66.4% over 1 year, 82.7% over 3 years, and 36.1% over 5 years. This raises fair questions about how much of the story is already reflected in the share price. Recent coverage of Incyte has focused on how the stock has re rated...
Incyte (INCY) Wins EU Backing For Opzelura As Pipeline Data Builds Across Four Drugs
Incyte (NasdaqGS: INCY) reported a favorable CHMP opinion for Opzelura in Europe for atopic dermatitis. The company released pivotal Phase 2 data for zilurgisertib in ultra rare fibrodysplasia ossificans progressiva. Phase 1 results for INCA033989 in mutCALR mutant myeloproliferative neoplasms showed strong clinical activity. Phase 3 frontMIND data for tafasitamab in first-line aggressive lymphomas indicated robust efficacy outcomes. For investors tracking Incyte, these updates highlight...